FI114796B - Menetelmä farmaseuttisesti aktiivisen (E)-3-[2-n-butyyli-1-{(4-karboksifenyyli)metyyli}-1H-imidatsol-5-yyli]-2-(2-tienyyli)metyyli-2-propeenihappometaanisulfonaatin valmistamiseksi - Google Patents
Menetelmä farmaseuttisesti aktiivisen (E)-3-[2-n-butyyli-1-{(4-karboksifenyyli)metyyli}-1H-imidatsol-5-yyli]-2-(2-tienyyli)metyyli-2-propeenihappometaanisulfonaatin valmistamiseksi Download PDFInfo
- Publication number
- FI114796B FI114796B FI940642A FI940642A FI114796B FI 114796 B FI114796 B FI 114796B FI 940642 A FI940642 A FI 940642A FI 940642 A FI940642 A FI 940642A FI 114796 B FI114796 B FI 114796B
- Authority
- FI
- Finland
- Prior art keywords
- methyl
- imidazol
- butyl
- carboxyphenyl
- thienyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- TUFPKOTYIVZFJR-XGRJIHFXSA-N CS(=O)(=O)O.C(CCC)C=1N(C(=CN1)/C(=C(C(=O)O)/C=1SC=CC1)/C)CC1=CC=C(C=C1)C(=O)O Chemical compound CS(=O)(=O)O.C(CCC)C=1N(C(=CN1)/C(=C(C(=O)O)/C=1SC=CC1)/C)CC1=CC=C(C=C1)C(=O)O TUFPKOTYIVZFJR-XGRJIHFXSA-N 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 8
- 230000008569 process Effects 0.000 title description 3
- -1 4-carboxyphenyl Chemical group 0.000 claims description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- BLPITTLHXKDNPJ-UHFFFAOYSA-N methylsulfonylurea Chemical compound CS(=O)(=O)NC(N)=O BLPITTLHXKDNPJ-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 31
- 108010064733 Angiotensins Proteins 0.000 description 12
- 102000015427 Angiotensins Human genes 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010019280 Heart failures Diseases 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 239000002876 beta blocker Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000036454 renin-angiotensin system Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102100028255 Renin Human genes 0.000 description 3
- 108090000783 Renin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000002254 renal artery Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 description 1
- GMVXCWQXIVFUHX-UHFFFAOYSA-N 1h-imidazol-2-yl prop-2-enoate Chemical class C=CC(=O)OC1=NC=CN1 GMVXCWQXIVFUHX-UHFFFAOYSA-N 0.000 description 1
- TWWVIBZNLDTRON-UHFFFAOYSA-N 2-(1-benzyl-2-butyl-5-chloroimidazol-4-yl)acetic acid Chemical compound CCCCC1=NC(CC(O)=O)=C(Cl)N1CC1=CC=CC=C1 TWWVIBZNLDTRON-UHFFFAOYSA-N 0.000 description 1
- ZLSNPZVGNMESDB-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)prop-2-enoic acid Chemical class OC(=O)C(=C)C1=NC=CN1 ZLSNPZVGNMESDB-UHFFFAOYSA-N 0.000 description 1
- OWZRRFCGWTXNTM-UHFFFAOYSA-N 2-(1h-imidazol-5-yl)propanoic acid Chemical class OC(=O)C(C)C1=CN=CN1 OWZRRFCGWTXNTM-UHFFFAOYSA-N 0.000 description 1
- ULRJKEVXFNLNIY-UHFFFAOYSA-N 2-(2-chloro-1h-imidazol-5-yl)acetic acid Chemical compound OC(=O)CC1=CNC(Cl)=N1 ULRJKEVXFNLNIY-UHFFFAOYSA-N 0.000 description 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- XYWDNESIXGLWDB-UHFFFAOYSA-N 3-(1-benzyl-5-chloro-2-phenylimidazol-4-yl)propanoic acid Chemical compound C=1C=CC=CC=1CN1C(Cl)=C(CCC(=O)O)N=C1C1=CC=CC=C1 XYWDNESIXGLWDB-UHFFFAOYSA-N 0.000 description 1
- FBGHBUADHGQJMQ-QNGOZBTKSA-N 4-[[2-butyl-5-[(E)-1-carboxy-1-thiophen-2-ylprop-1-en-2-yl]imidazol-1-yl]methyl]benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C(C)=C(/C(O)=O)C1=CC=CS1 FBGHBUADHGQJMQ-QNGOZBTKSA-N 0.000 description 1
- HXHGULXINZUGJX-UHFFFAOYSA-N 4-chlorobutanol Chemical compound OCCCCCl HXHGULXINZUGJX-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000008068 Tensins Human genes 0.000 description 1
- 108010088950 Tensins Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229910001514 alkali metal chloride Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical class CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- CYPPHOGCEHKEHQ-UHFFFAOYSA-N ethyl 3-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]prop-2-enoate Chemical compound C=1C=C(F)C=CC=1N1C(C=CC(=O)OCC)=C(C(C)C)N=C1C1=CC=CC=C1 CYPPHOGCEHKEHQ-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- PRJKNHOMHKJCEJ-UHFFFAOYSA-N imidazol-4-ylacetic acid Chemical class OC(=O)CC1=CN=CN1 PRJKNHOMHKJCEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- LLBAPKIIGXPQIC-UHFFFAOYSA-N methanesulfonic acid;prop-2-enoic acid Chemical compound CS(O)(=O)=O.OC(=O)C=C LLBAPKIIGXPQIC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229940025703 topical product Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/746,262 US5185351A (en) | 1989-06-14 | 1991-08-14 | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
| US74626291 | 1991-08-14 | ||
| US9206734 | 1992-08-12 | ||
| PCT/US1992/006734 WO1993003722A1 (en) | 1991-08-14 | 1992-08-12 | Imidazolyl-alkenoic acids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI940642L FI940642L (fi) | 1994-02-11 |
| FI940642A0 FI940642A0 (fi) | 1994-02-11 |
| FI114796B true FI114796B (fi) | 2004-12-31 |
Family
ID=25000103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI940642A FI114796B (fi) | 1991-08-14 | 1994-02-11 | Menetelmä farmaseuttisesti aktiivisen (E)-3-[2-n-butyyli-1-{(4-karboksifenyyli)metyyli}-1H-imidatsol-5-yyli]-2-(2-tienyyli)metyyli-2-propeenihappometaanisulfonaatin valmistamiseksi |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5185351A (cs) |
| EP (1) | EP0641203B1 (cs) |
| JP (1) | JPH07500579A (cs) |
| CN (1) | CN1036396C (cs) |
| AP (3) | AP527A (cs) |
| AT (1) | ATE226073T1 (cs) |
| AU (1) | AU667824B2 (cs) |
| BG (1) | BG61593B1 (cs) |
| BR (1) | BR9206443A (cs) |
| CA (1) | CA2115170C (cs) |
| CZ (1) | CZ281635B6 (cs) |
| DE (1) | DE69232817T2 (cs) |
| DK (1) | DK0641203T3 (cs) |
| ES (1) | ES2185617T3 (cs) |
| FI (1) | FI114796B (cs) |
| HU (1) | HU225048B1 (cs) |
| IL (1) | IL102813A (cs) |
| MA (1) | MA22626A1 (cs) |
| MX (1) | MX9204737A (cs) |
| MY (1) | MY110205A (cs) |
| NO (1) | NO305172B1 (cs) |
| NZ (1) | NZ243966A (cs) |
| OA (1) | OA09884A (cs) |
| PL (1) | PL177234B1 (cs) |
| PT (1) | PT100779B (cs) |
| RO (1) | RO113643B1 (cs) |
| RU (1) | RU2124513C1 (cs) |
| SK (1) | SK281252B6 (cs) |
| TW (1) | TW234690B (cs) |
| UA (1) | UA40587C2 (cs) |
| WO (1) | WO1993003722A1 (cs) |
| ZA (1) | ZA926133B (cs) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5418250A (en) * | 1989-06-14 | 1995-05-23 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
| US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
| US6034114A (en) * | 1990-12-14 | 2000-03-07 | Smithkline Beecham Plc | Medicament |
| WO1992010189A1 (en) * | 1990-12-14 | 1992-06-25 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
| US6025380A (en) * | 1990-12-14 | 2000-02-15 | Smithkline Beecham Plc | Medicament |
| US6028091A (en) * | 1990-12-14 | 2000-02-22 | Smithkline Beecham Plc | Medicament |
| GB9027200D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| US5447949A (en) * | 1991-05-15 | 1995-09-05 | Smithkline Beecham Corporation | N-(heteroaryl) imidazolyl-alkenoic acids having angiotension II receptor antagonist activity |
| US20030166700A1 (en) * | 1991-12-12 | 2003-09-04 | Smithkline Beecham P.L.C. | Medicament |
| US5308853A (en) * | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
| DE4206043A1 (de) * | 1992-02-27 | 1993-09-02 | Bayer Ag | Sulfonylbenzyl-substituierte imidazole |
| US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| US5824696A (en) * | 1993-09-01 | 1998-10-20 | Smithkline Beecham Corporation | Medicaments |
| US5395847A (en) * | 1993-12-02 | 1995-03-07 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
| US5719293A (en) * | 1994-05-20 | 1998-02-17 | Smithkline Beecham Corporation | Intermediate for preparing a pharmaceutically active compound |
| HUT76344A (en) * | 1994-06-29 | 1997-08-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| US6613789B2 (en) | 1994-07-28 | 2003-09-02 | G. D. Searle & Co. | Heterocyclo-substituted imidazoles for the treatment of inflammation |
| US5977101A (en) * | 1995-06-29 | 1999-11-02 | Smithkline Beecham Corporation | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity |
| US6420412B2 (en) | 1996-03-29 | 2002-07-16 | Smithkline Beecham Corporation | Eprosartan dihydate and a process for its production and formulation |
| HU228263B1 (en) * | 1996-03-29 | 2013-02-28 | Smithkline Beecham Corp | Eprosartan dihydrate and a process for its production and formulation |
| AR011125A1 (es) * | 1997-02-14 | 2000-08-02 | Smithkline Beecham Corp | Procedimiento para preparar eprosartano |
| AR011126A1 (es) | 1997-02-14 | 2000-08-02 | Smithkline Beecham Corp | Procedimiento para preparar eprosartano y compuestos intermediarios. |
| US20030045561A1 (en) * | 2001-02-06 | 2003-03-06 | Smithkline Beecham Corporation | Method of treating isolated systolic hypertension |
| ZA984421B (en) * | 1997-05-27 | 1998-11-27 | Smithkline Beecham Corp | Method of treating isolated systolic hypertension |
| WO1999000383A1 (en) * | 1997-06-27 | 1999-01-07 | Smithkline Beecham Corporation | Eprosartan monohydrate |
| US6630498B2 (en) | 1997-08-06 | 2003-10-07 | Smithkline Beecham Corporation | Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation |
| ES2273433T3 (es) * | 1997-08-06 | 2007-05-01 | Smithkline Beecham Corporation | Complejo por neutralizacion de cargas con arginilo de eprosartan y procedimiento para su produccion y formulacion. |
| EP1033974B1 (en) * | 1997-11-17 | 2014-01-22 | GlaxoSmithKline LLC | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
| US6558699B2 (en) * | 1997-11-17 | 2003-05-06 | Smithkline Beecham Corporation | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
| ZA991922B (en) * | 1998-03-11 | 1999-09-13 | Smithkline Beecham Corp | Novel compositions of eprosartan. |
| NZ509378A (en) * | 1998-07-20 | 2003-04-29 | Smithkline Beecham Corp | Amorphous ammonium salts of eprosartan and pharmaceuticals thereof, useful for blocking angiotensin II receptors and useful for treating hypertension, congestive heart disease and renal failure |
| CN1177835C (zh) | 1998-07-24 | 2004-12-01 | 拜尔公司 | 取代的苯甲酰基环己二酮类化合物 |
| DE19920791A1 (de) | 1999-05-06 | 2000-11-09 | Bayer Ag | Substituierte Benzoylisoxazole |
| DE19921424A1 (de) | 1999-05-08 | 2000-11-09 | Bayer Ag | Substituierte Benzoylketone |
| DE19946853A1 (de) | 1999-09-30 | 2001-04-05 | Bayer Ag | Substituierte Arylketone |
| DE10004084A1 (de) * | 2000-01-31 | 2001-08-02 | Bayer Ag | Substituierte Imid-Derivate |
| DE10221121A1 (de) * | 2002-05-13 | 2003-12-04 | Bayer Cropscience Ag | N'-Cyano-N-methyl-imidamid-Derivate |
| GEP20074134B (en) | 2002-08-19 | 2007-06-25 | Pfizer Prod Inc | Combination therapy for hyperproliferative diseases |
| EP1658283A2 (en) * | 2003-05-30 | 2006-05-24 | Ranbaxy Laboratories, Ltd. | Substituted pyrrole derivatives and their use as hmg-co inhibitors |
| US20050037063A1 (en) * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies |
| CA2541867C (en) * | 2003-10-10 | 2012-06-12 | Solvay Pharmaceuticals Gmbh | Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker |
| US20060099230A1 (en) * | 2004-11-10 | 2006-05-11 | Chin-Chih Chiang | Novel formulations of eprosartan with enhanced bioavailability |
| ATE439347T1 (de) * | 2004-11-23 | 2009-08-15 | Warner Lambert Co | 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia |
| EP1752450A1 (en) | 2005-08-01 | 2007-02-14 | Merck Sante | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| BRPI0618379A2 (pt) * | 2005-11-08 | 2011-08-30 | Ranbaxy Lab Ltd | processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| CN101312962A (zh) * | 2005-12-06 | 2008-11-26 | 参天制药株式会社 | 角膜结膜病变的治疗剂 |
| AR059838A1 (es) * | 2006-03-14 | 2008-04-30 | Ranbaxy Lab Ltd | Formulaciones para dosis estabilizantes de estatina |
| US20080153896A1 (en) * | 2006-07-14 | 2008-06-26 | Gyan Chand Yadav | Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof |
| US20080014263A1 (en) * | 2006-07-17 | 2008-01-17 | Glenmark Pharmaceuticals Limited | Amorphous eprosartan mesylate and process for the preparation thereof |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| US20100137613A1 (en) * | 2006-12-27 | 2010-06-03 | Hetero Drugs Limited | Process for eprosartan |
| CN101772513B (zh) | 2007-06-04 | 2013-11-13 | 协同医药品公司 | 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2295430A3 (en) * | 2007-07-25 | 2011-08-03 | Hetero Drugs Limited | Crystalline solid of eprosartan acetate |
| US8361507B2 (en) * | 2007-07-25 | 2013-01-29 | Hetero Drugs Limited | Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan |
| CA2703231A1 (en) * | 2007-10-22 | 2009-04-30 | Orchid Research Laboratories Limited | Histone deacetylase inhibitors |
| WO2009084028A2 (en) * | 2007-12-03 | 2009-07-09 | Neuland Laboratories Ltd | Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate |
| CN101215284B (zh) * | 2007-12-31 | 2010-10-13 | 浙江华海药业股份有限公司 | 一种改进的依普罗沙坦的制备方法 |
| WO2009122421A2 (en) * | 2008-03-31 | 2009-10-08 | Hetero Research Foundation | Improved process for eprosartan intermediate |
| EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| CN101333216A (zh) | 2008-08-03 | 2008-12-31 | 浙江华海药业股份有限公司 | 一种新的依普罗沙坦甲磺酸盐成盐工艺 |
| WO2010075347A2 (en) | 2008-12-23 | 2010-07-01 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone |
| WO2011004384A2 (en) | 2009-06-05 | 2011-01-13 | Glochem Industries Limited | Process for the preparation of eprosartan |
| WO2011051975A1 (en) | 2009-10-30 | 2011-05-05 | Matrix Laboratories Ltd | An improved process for the preparation of pure eprosartanand its pharmaceutical acceptable salts |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| RU2525156C2 (ru) * | 2010-07-15 | 2014-08-10 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения и профилактики артериальной гипертензии и фармацевтическая композиция для лечения артериальной гипертензии |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| MX2014002163A (es) | 2011-08-26 | 2014-09-25 | Wockhardt Ltd | Métodos para el tratamiento de desórdenes cardiovasculares. |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| SG11201507496UA (en) | 2013-04-17 | 2015-11-27 | Pfizer | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| EA201592263A1 (ru) | 2013-06-05 | 2016-05-31 | Синерджи Фармасьютикалз, Инк. | Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования |
| EP3025711B1 (en) | 2013-07-23 | 2020-11-18 | Daiichi Sankyo Company, Limited | Medicine for preventing or treating hypertension |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| CN108778334A (zh) | 2016-03-24 | 2018-11-09 | 第三共株式会社 | 用于治疗肾脏疾病的药物 |
| CA3103599A1 (en) | 2018-06-14 | 2019-12-19 | Astrazeneca Uk Limited | Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition |
| JOP20210193A1 (ar) | 2019-01-18 | 2023-01-30 | Astrazeneca Ab | مثبطات pcsk9 وطرق استخدامها |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5671073A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | Imidazole derivative |
| JPS5671074A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
| JPS58157768A (ja) * | 1982-03-16 | 1983-09-19 | Takeda Chem Ind Ltd | ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体 |
| US4668794A (en) * | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
| CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| EP0955294B1 (en) * | 1989-06-14 | 2003-09-24 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acid |
| US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
| CA2027937A1 (en) * | 1989-10-25 | 1991-04-26 | Richard M. Keenan | Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles |
| GB9027197D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| DE69131021T2 (de) * | 1990-12-14 | 1999-08-12 | Smithkline Beecham Corp., Philadelphia, Pa. 19101 | Angiotensin-ii-rezeptor blockierende zusammensetzungen |
| GB9027201D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027211D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027210D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| WO1992010189A1 (en) * | 1990-12-14 | 1992-06-25 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
| GB9027200D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027198D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027208D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027212D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027199D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027209D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
-
1991
- 1991-08-14 US US07/746,262 patent/US5185351A/en not_active Expired - Lifetime
-
1992
- 1992-08-12 SK SK135-94A patent/SK281252B6/sk not_active IP Right Cessation
- 1992-08-12 HU HU9400413A patent/HU225048B1/hu unknown
- 1992-08-12 RO RO94-00225A patent/RO113643B1/ro unknown
- 1992-08-12 JP JP5504405A patent/JPH07500579A/ja active Pending
- 1992-08-12 AU AU24756/92A patent/AU667824B2/en not_active Ceased
- 1992-08-12 UA UA94021675A patent/UA40587C2/uk unknown
- 1992-08-12 RU RU94018226A patent/RU2124513C1/ru active
- 1992-08-12 CA CA002115170A patent/CA2115170C/en not_active Expired - Lifetime
- 1992-08-12 DE DE69232817T patent/DE69232817T2/de not_active Expired - Lifetime
- 1992-08-12 BR BR9206443A patent/BR9206443A/pt not_active IP Right Cessation
- 1992-08-12 CZ CZ94311A patent/CZ281635B6/cs not_active IP Right Cessation
- 1992-08-12 ES ES92918356T patent/ES2185617T3/es not_active Expired - Lifetime
- 1992-08-12 EP EP92918356A patent/EP0641203B1/en not_active Expired - Lifetime
- 1992-08-12 WO PCT/US1992/006734 patent/WO1993003722A1/en active IP Right Grant
- 1992-08-12 AT AT92918356T patent/ATE226073T1/de active
- 1992-08-12 DK DK92918356T patent/DK0641203T3/da active
- 1992-08-12 PL PL92302397A patent/PL177234B1/pl unknown
- 1992-08-13 MA MA22915A patent/MA22626A1/fr unknown
- 1992-08-14 AP APAP/P/1995/000742A patent/AP527A/en active
- 1992-08-14 MY MYPI92001466A patent/MY110205A/en unknown
- 1992-08-14 AP APAP/P/1992/000416A patent/AP525A/en active
- 1992-08-14 PT PT100779A patent/PT100779B/pt not_active IP Right Cessation
- 1992-08-14 CN CN92110883A patent/CN1036396C/zh not_active Expired - Lifetime
- 1992-08-14 AP APAP/P/1995/000741A patent/AP526A/en active
- 1992-08-14 IL IL10281392A patent/IL102813A/en not_active IP Right Cessation
- 1992-08-14 MX MX9204737A patent/MX9204737A/es active IP Right Grant
- 1992-08-14 NZ NZ243966A patent/NZ243966A/en unknown
- 1992-08-14 ZA ZA926133A patent/ZA926133B/xx unknown
- 1992-08-20 TW TW081106595A patent/TW234690B/zh not_active IP Right Cessation
-
1994
- 1994-02-10 OA OA60471A patent/OA09884A/en unknown
- 1994-02-11 NO NO940476A patent/NO305172B1/no not_active IP Right Cessation
- 1994-02-11 BG BG98454A patent/BG61593B1/bg unknown
- 1994-02-11 FI FI940642A patent/FI114796B/fi not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI114796B (fi) | Menetelmä farmaseuttisesti aktiivisen (E)-3-[2-n-butyyli-1-{(4-karboksifenyyli)metyyli}-1H-imidatsol-5-yyli]-2-(2-tienyyli)metyyli-2-propeenihappometaanisulfonaatin valmistamiseksi | |
| EP0403159B1 (en) | Imidazolyl-alkenoic acids | |
| US5212176A (en) | R(+)-terazosin | |
| SU1277894A3 (ru) | Способ получени 3-/1-имидазолилалкил/индолов или их фармацевтически приемлемых кислотно-аддитивных солей | |
| US5444081A (en) | Substituted histidines having angiotension II receptor antagonist activity | |
| DK2616068T3 (en) | ESTER prodrugs of the [3- (1- (1H-imidazol-4-yl) ethyl) -2-methyl-phenyl] -methanol for lowering intraocular pressure | |
| WO1994020460A1 (en) | Chemical compounds | |
| IE903976A1 (en) | Substituted n-(imidazolyl)alkyl alanine derivatives | |
| EP0563238B1 (en) | Imidazolyl-alkenoic acids | |
| JP2000512291A (ja) | 新規な化合物 | |
| US5234917A (en) | Substituted 5-(alkyl)carboxamide imidazoles | |
| HUT62576A (en) | Process for producing substituted imidazolylpropenoic acid derivatives and pharmaceutical compositions comprising such compounds | |
| US5294633A (en) | Imidazolyl-propenoic acid derivatives | |
| US4683229A (en) | 6-halo-9-alkenyleneoxy-3-alkyl-2,3,4,5-tetrahydro-(1H-3)-benzazepines and their use as selective alpha-adrenergic receptor antagonists | |
| JPH0139425B2 (cs) | ||
| EP0559755A1 (en) | Substituted 5-aryl imidazoles | |
| CZ301913B6 (cs) | Farmaceutický prípravek pro predcházení, lécení nebo inhibování vývoje jednoduché retinopatie nebo predproliferacní retinopatie | |
| US5395847A (en) | Imidazolyl-alkenoic acids | |
| TW379220B (en) | Pyrazolidine derivative, radical scavenger, brain--infarction depressant, and brain-edma depressant | |
| HK1012384B (en) | Imidazolyl-alkenoic acids | |
| IE42878B1 (en) | 4-amino-3-benzylideneamino-1,2,4-triazoles-methods for their preparation and their use | |
| HK1012246B (en) | Pharmaceutical compositions of an imidazolyl-akenoic acid salt and their use as angiotensin ii antagonists | |
| SI9200228A (sl) | Imidazolil-alkenojske kisline | |
| JPH02142784A (ja) | シクロプロパベンゾチオピラノン化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |